Внепищеводные симптомы гастроэзофагеальной рефлюксной болезни: в фокусе ларингофарингеальный рефлюкс

1. Dent J, Brun J, Fendrick A et al. An evidence-based appraisal of reflux disease management – the Genval Workshop Report. Gut 1999; 44 (Suppl. 2): S1–16. DOI: 10.1136/gut.44.2008.s1
2. Ивашкин В.Т., Маев И.В., Трухманов А.С. и др. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению гастроэзофагеальной рефлюксной болезни. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2020; 30 (4): 70–97. DOI: 10.22416/1382-4376-2020-30-4-70-97
[Ivashkin V.T., Maev I.V., Trukhmanov A.S. et al. Recommendations of the Russian Gastroenterological Association in Diagnosis and Treatment of Gastroesophageal Reflux Disease. Rus J Gastroenterol Hepatol Coloproctol. 2020; 30 (4): 70–97. DOI: 10.22416/1382-4376-2020-30-4-70-97 (in Russian).]
3. Vakil N, van Zanten SV, Kahrilas P et al. Montreal definition and classification of gastroesophageal reflux disease: a global evidence – based consensus. Am J Gastroenterol 2006; 101 (8): 1900–20. https://www.unboundmedicine.com/medline/citation/16928254/The_Montreal_definition_and_classification...
4. Глобальные практические рекомендации Всемирной гастроэнтерологической организации. ГЭРБ. http://www.worldgastroenterology.org/guidelines/global-guidelines/gastroesophageal-reflux-disease/ga...
[Global Practical Guidelines of the World Gastroenterological Organization. GERD. http://www.worldgastroenterology.org/guidelines/global-guidelines/gastroesophageal-reflux-disease/ga... (in Russian).]
5. Трухан Д.И., Тарасова Л.В. Гастроэзофагеальная рефлюксная болезнь в практике врача первого контакта. Рос. медицинские вести. 2013; 1: 16–25. https://www.gastroscan.ru/literature/authors/6875 
[Trukhan D.I., Tarasova L.V. Gastroesophageal reflux disease practice of the first contact doctor. Rus Med News. 2013; 1: 16–25. https://www.gastroscan.ru/literature/authors/6875 (in Russian).]
6. Трухан Д.И., Филимонов С.Н. Дифференциальный диагноз основных гастроэнтерологических синдромов и симптомов. М.: Практическая медицина, 2016. https://www.litres.ru/dmitriy-truhan/differencialnyy-diagnoz-osnovnyh-gastroenterologic-57081630/
[Trukhan D.I., Filimonov S.N. Differential diagnosis of major gastroenterological syndromes and symptoms. Moscow: Practical medicine, 2016. https://www.litres.ru/dmitriy-truhan/differencialnyy-diagnoz-osnovnyh-gastroenterologic-57081630/ (in Russian).]
7. Тарасова Л.В., Трухан Д.И. Изжога – актуальные вопросы дифференциальной диагностики и лечения. Медицинский альманах. 2013; 1: 91–5. https://elibrary.ru/item.asp?id=18910551
[Tarasova L.V., Trukhan D.I. Heartburnpresent-day aspects of differential diagnostics and treatment. Med Almanac. 2013; 1: 91–5. https://elibrary.ru/item.asp?id=18910551 (in Russian).]
8. Трухан Д.И., Тарасова Л.В. Диагностическая и лечебная тактика врача общей практики при изжоге. Справочник врача общей практики. 2013; 4: 19–26. https://www.elibrary.ru/item.asp?id=20469510 
[Trukhan D.I., Tarasova L.V. Diagnostic and therapeutic tactics of general practitioner with heartburn. J Family Med. 2013; 4: 19–26. https://www.elibrary.ru/item.asp?id=20469510 (in Russian).]
9. Трухан Д.И. Диагностическая и лечебная тактика при изжоге на этапе оказания первичной медико-санитарной помощи. Consilium Medicum. 2016; 18 (1): 17–22. https://www.elibrary.ru/item.asp?id=26211004
[Trukhan D.I. Diagnostic and treatment policy with heartburn at the stage of primary health care. Consilium Medicum. 2016; 18 (1): 17–22. https://www.elibrary.ru/item.asp?id=26211004 (in Russian).]
10. Трухан Д.И., Викторова И.А. Гастроэзофагеальная рефлюксная болезнь: актуальные аспекты диагностики и лечения в реальной клинической практике терапевта. Медицинский совет. 2019; 14: 22–31. DOI: 10.21518/2079-701X2019-14-22-31
[Trukhan D.I., Viktorova I.A. Gastroesophageal reflux disease: actual aspects of diagnostics and treatment in real clinical practice of therapist. Medical Council. 2019; 14: 22–31. DOI: 10.21518/2079-701X-2019-14-22-31 (in Russian).]
11. Гришечкина И.А., Трухан Д.И. Особенности психовегетативного статуса и серотонинэргической системы при различных клинических вариантах гастроэзофагеального рефлюкса. Экспериментальная и клиническая гастроэнтерология. 2014; 9 (109): 48–51. https://elibrary.ru/item.asp?id=22677293
[Grishechkina I.A., Trukhan D.I. The role of psychovegetative status and serotonergic system in patients with gastroesophageal reflux disease. Exp Clin Gastroenterol. 2014; 9 (109): 48–51. https://elibrary.ru/item.asp?id=22677293 (in Russian).]
12. Трухан Д.И., Гришечкина И.А. Актуальные аспекты антисекреторной терапии гастроэзофагеальной рефлюксной болезни. Медицинский совет. 2017; 15: 28–35. DOI: 10.21518/2079-701X-2017-15-28-35
[Trukhan D.I., Grishechkina I.A. Actual aspects of anti-secretor therapy of gastroesophageal reflux disease. Medical Council. 2017; 15: 28–35. DOI: 10.21518/2079-701X-2017-15-28-35 (in Russian).]
13. Маев И.В., Юренев Г.Л., Дичева Д.Т. и др. Пульмонологическая маска гастроэзофагеальной рефлюксной болезни. Consilium Medicum. 2012; 14 (1): 15–8. https://con-med.ru/magazines/gastroenterology/gastroenterology-01-2012/pulmonologicheskaya_maska_gas...
[Mayev I.V., Yurenev G.L., Dicheva D.T. et al. Pulmonary mask of gastroesophageal reflux disease. Consilium Medicum. 2012; 14 (1): 15–8. https://con-med.ru/magazines/gastroenterology/gastroenterology-01-2012/pulmonologicheskaya_maska_gas... (in Russian).] 
14. Трухан Л.Ю., Трухан Д.И., Викторова И.А. Изменения органов и тканей полости рта при заболеваниях внутренних органов. Справочник поликлинического врача. 2011; 7: 8–14. https://elibrary.ru/item.asp?id=23605228
[Trukhan L.Yu., Trukhan D.I., Viktorova I.A. Changes in the organs and tissues of the oral 
cavity with diseases of the internal organs. Handbook for Practitioners Doctors. 2011; 7: 8–14. 
https://elibrary.ru/item.asp?id=23605228 (in Russian).]
15. Ивашкин В.Т., Маев И.В., Трухманов А.С., Румянцева Д.Е. Современные достижения в диагностике и лечении рефрактерной формы гастроэзофагеальной рефлюксной болезни. Терапевтический архив. 2018; 90 (8): 4–12. DOI: 10.26442/terarkh20189084-12
[Ivashkin V.T., Maev I.V., Truhmanov A.S., Rumntseva D.E. Modern achievements in the diagnosis and treatment of the refractory gastroesophageal reflux disease. Therapeutic Archive. 2018; 90 (8): 4–12. DOI: 10.26442/terarkh20189084-12 (in Russian).]
16. Трухан Д.И., Голошубина В.В., Трухан Л.Ю. Изменения со стороны органов и тканей полости рта при гастроэнтерологических заболеваниях. Эксперим. и клин. гастроэнтерология. 2015; 3 (115): 90–3. https://cyberleninka.ru/article/n/izmeneniya-so-storony-organov-i-tkaney-polosti-rta-pri-gastroenter...
[Trukhan D.I., Goloshubina V.V., Trukhan L.Yu. Changes in the organs and tissues of the oral cavity with digestive system diseases. Exp Clin Gastroenterol. 2015; 3 (115): 90–3. https://cyberleninka.ru/article/n/izmeneniya-so-storony-organov-i-tkaney-polosti-rta-pri-gastroenter... (in Russian).]
17. Юренев Г.Л., Самсонов А.А., Юренева-Тхоржевская Т.В. Современный взгляд на кардиальные проявления гастроэзофагеальной рефлюксной болезни. Consilium Medicum. 2015; 17 (12): 44–9. DOI: 10.26442/2075-1753_2015.12.44-49
[Yurenev G.L., Samsonov A.A., Yureneva-Tkhorzhevskaya T.V. Modern look at cardiac manifestations of gastroesophageal reflux disease. Consilium Medicum. 2015; 17 (12): 44–9. DOI: 10.26442/2075-1753_2015.12.44-49 (in Russian).] 
18. Юренев Г.Л., Самсонов А.А., Юренева-Тхоржевская Т.В., Маев И.В. Бронхообструктивный синдром у больных с гастроэзофагеальной рефлюксной болезнью: внепищеводное проявление заболевания или бронхиальная астма? Consilium Medicum. 2014; 16 (2): 33–38. https://www.elibrary.ru/item.asp?id=21994300
[Yurenev G.L., Samsonov A.A., Yureneva-Tkhorzhevskaya T.V., Maev I.V. Bronchoobstructive syndrome in patients with gastroesophageal reflux disease: extraesophageal manifestations of the disease or bronchial asthma? Consilium Medicum. 2014; 16 (2): 33–38. https://www.elibrary.ru/item.asp?id=21994300 (in Russian).]
19. Маев И.В., Юренев Г.Л., Юренева-Тхоржевская Т.В. Клиническое значение вариабельности сердечного ритма у пациентов с гастроэзофагеальной рефлюксной болезнью. Клин. медицина. 2016; 8: 574–82. DOI: 10.18821/0023-2149-2016-94-8-574-582
[Maev I.V., Yurenev G. L., Yureneva-Tkhorzhevskaya T.V. Clinical significance of heart rhythm variability in patients with gastroesophageal reflux disease. Clin Med. 2016; 8: 574–82. DOI: 10.18821/0023-2149-2016-94-8-574-582 (in Russian).]
20. Трухан Л.Ю., Трухан Д.И. Стоматологические проблемы гастроэнтерологических пациентов и возможные пути их решения. Медицинский совет. 2016; 19: 134–7. DOI: 10.21518/2079-701X-2016-19-134-137
[Trukhan L.Yu., Trukhan D.I. Stomatoligical problems of gastroenterological patients and their possible solutions. Medical Council. 2016; 19: 134–7. DOI: 10.21518/2079-701X-2016-19-134-137 (in Russian).]
21. Jaspersen D, Kulig M, Labenz J et al. Prevalence of extraoesophageal manifestations in gastro-oesophageal reflux disease: an analysis based on the ProGERD Study. Aliment Pharmacol Ther 2003; 17: 1515–20. DOI: 10.1046/j.1365- 2036.2003.01606.x
22. Bayliss EA, Steiner JF, Fernald DH et al. Descriptions of barriers to self-care by persons with comorbid chronic diseases. Ann Fam Med 2003; 1 (1): 15–21. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1466563/
23. Hughes LD, McMurdo ME, Guthrie B. Guidelines for people not for diseases: the challenges of applying UK clinical guidelines to people with multimorbidity. Age Ageing 2013; 42 (1): 62–9. DOI: 10.1093/ageing/afs100 
24. Ferrer A, Formiga F, Sanz H et al. Multimorbidity as specific disease combinations, an important predictor factor for mortality in octogenarians: the Octabaix study. Clin Interv Aging 2017; 12: 223–31. DOI: 10.2147/CIA.S123173. 
25. Трухан Д.И., Коншу Н.В. Рациональная фармакотерапия в клинике внутренних болезней сквозь призму мультиморбидности и лекарственной безопасности. Справочник поликлинического врача. 2019; 2: 10–8. https://www.elibrary.ru/item.asp?id=44162870
[Trukhan D.I., Konshu N.V. Rational pharmacotherapy in the clinic of internal diseases through the prism of multimorbidity and drug safety.  Handbook for Practitioners Doctors. 2019; (2): 10–8. https://www.elibrary.ru/item.asp?id=44162870 (in Russian).] 
26. Трухан Д.И., Тарасова Л.В. Клиника, диагностика и лечение хронического дуоденита. Эксперим. и клин. гастроэнтерология. 2012; 11: 104–14. https://elibrary.ru/item.asp?id=21589957
[Trukhan D.I., Tarasova L.V. The clinical symptoms, diagnostics and treatment of chronic duodenitis. Exp Clin Gastroenterol. 2012; 11: 104–14. https://elibrary.ru/item.asp?id=21589957 (in Russian).]
27. Хлынова О.В., Туев А.В., Береснева Л.Н., Агафонов А.В. Проблема коморбидности с учетом состояния сердечно-сосудистой системы у пациентов с артериальной гипертензией и кислотозависимыми заболеваниями. Казанский мед. журнал. 2013; 1: 80–5. https://elibrary.ru/item.asp?id=18794502
[Khlynova O.V., Tuev A.V., Beresneva L.N., Agafonov A.V. The problem of concomitant diseases with a focus on the cardiovascular system condition in patients with arterial hypertension and acid-related diseases. Kazan Med J. 2013; 1: 80–5. https://elibrary.ru/item.asp?id=18794502 (in Russian).]
28. Трухан Д.И., Тарасова Л.В., Трухан Л.Ю. Гастроэнтерологические нарушения у пациентов с сахарным диабетом. Справочник врача общей практики. 2013; 8: 51–9. https://www.elibrary.ru/item.asp?id=20469561
[Trukhan D.I., Tarasova L.V., Trukhan L.Y. Gastroenterological disorders of patients with diabetes mellitus. J Family Med. 2013; 8: 51–9. https://www.elibrary.ru/item.asp?id=20469561 (in Russian).]
29. Трухан Д.И., Голошубина В.В., Трухан Л.Ю. Изменения верхних отделов желудочно-кишечного тракта у пациентов с сахарным диабетом: актуальные вопросы диагностики, лечения и контроля. Справочник поликлинического врача. 2014; 11: 40–3. https://www.elibrary.ru/item.asp?id=23417344 
[Trukhan D.I., Goloshubina V.V., Trukhan L.Yu.  Changes in the upper gastrointestinal tract in patients with diabetes mellitus: topical issues of diagnosis, treatment and control.  Handbook for Practitioners Doctors. 2014; 11: 40–3. https://www.elibrary.ru/item.asp?id=23417344 (in Russian).]
30. Юренев Г.Л., Казюлин А.Н., Юренева-Тхоржевская Т.В. Влияние кислотосупрессивной терапии на клиническое течение ишемической болезни сердца с рефрактерным болевым синдромом в грудной клетке. Терапия. 2015; 2: 28–36. https://elibrary.ru/item.asp?id=25471414 
[Yurenev G.L., Kazyulin A.N., Yureneva-Tkhorzhevskaya T.V. The influence of acid-suppressive therapy on the clinical course of ischemic heart disease with refractory pain syndrome in the chest. Therapy. 2015; 2: 28–36. https://elibrary.ru/item.asp?id=25471414 (In Russ.)]
31. Бурков С.Г., Касимцева Е.В., Агафонова Л.Ю. и др. Состояние верхних отделов пищеварительного тракта и рациональный выбор антисекреторной терапии у пациентов старческого возраста. Фарматека. 2015; 2: 56–61. https://pharmateca.ru/ru/archive/article/30798
[Burkov S.G., Kasimtseva E.V., Agafonova L.Yu. State of the upper digestive tract and rational choice of antisecretory therapy in elderly patients. Farmateka. 2015; 2: 56–61. https://pharmateca.ru/ru/archive/article/30798 (in Russian).]
32. Юренев Г.Л., Миронова Е.М., Андреев Д.Н., Юренева-Тхоржевская Т.В. Клинические и патогенетические параллели гастроэзофагеальной рефлюксной болезни и ожирения. Фарматека. 2017; 13: 30–9. https://www.gastroscan.ru/literature/authors/9856
[Yurenev G.L., Mironova E.M., Andreev D.N., Yureneva-Thorzhevskaya T.V. Clinical and pathogenetic parallels gastroesophageal reflux disease and obesity. Farmateka. 2017; 13: 30–9. https://www.gastroscan.ru/literature/authors/9856 (in Russian).]
33. Щербенков И.М., Стасева И.В. Полиморбидный пациент: в фокусе гастроэзофагеальная рефлюксная болезнь. Consilium Medicum. 2018; 20 (8): 24–31. DOI: 10.26442/2075-1753_2018.8.24-31
[Shcherbenkov I.M., Staseva I.V. Multimorbid patient: gastro-esophageal reflux disease in focus. Consilium Medicum. 2018; 20 (8): 24–31. DOI: 10.26442/2075-1753_2018.8.24-31 (in Russian).]
34. Koufman JA. The otolaryngologic manifestations of gastroesophageal reflux disease (GERD): a clinical investigation of 225 patients using ambulatory 24-hour pH monitoring and an experimental investigation of the role of acid and pepsin in the development of laryngeal injury. Laryngoscope 1991; 101 (Suppl. 53): 1–78. DOI: 10.1002/lary.1991.101.s53.1
35. Koufman JA, Aviv JE, Casiano RR, Shaw GY. Laryngopharyngeal reflux: Position statement of the Committee on Speech, Voice, and Swallowing Disorders of the American Academy of Otolaryngology–Head and Neck Surgery. Otolaryngol Head Neck Surg 2002; 127 (1): 32–5. DOI: 10.1067/mhn.2002.125760
36. Анготоева И.Б., Мулдашева А.А. Современные представления о проблеме ларингофарингеального рефлюкса. Медицинский совет. 2015; 15: 44–9. https://elibrary.ru/item.asp?id=25319236
[Angotoeva I.B., Muldasheva A.A. Current views on the problem of laryngopharyngeal reflux. Medical Council. 2015; 15: 44–9. https://elibrary.ru/item.asp?id=25319236 (in Russian).]
37. Яровой И.Ю., Ниделько А.А., Буцель А.Ч. Ларингофарингеальный рефлюкс. Медицинский журнал. 2015; 3: 29–34. https://elibrary.ru/item.asp?id=24251748
[Yaravy I. Yu., Nidelko A.A., Bycel A.G. Laryngopharyngeal reflux. Medical J. 2015; 3: 29–34. https://elibrary.ru/item.asp?id=24251748 (in Russian).]
38. Lechien JR, Saussez S, Karkos PD. Laryngopharyngeal reflux disease: clinical presentation, diagnosis and therapeutic challenges in 2018. Curr Opin Otolaryngol Head Neck Surg 2018; 26 (6): 392–402. DOI: 10.1097/MOO.0000000000000486
39. Lechien JR, Akst LM, Hamdan AL et al. Evaluation and Management of Laryngopharyngeal Reflux Disease: State of the Art Review. Otolaryngol Head Neck Surg 2019; 160 (5): 762–82. DOI: 10.1177/0194599819827488
40. Hammer HF. Reflux-associated laryngitis and laryngopharyngeal reflux: a gastroenterologist's point of view. Dig Dis 2009; 27 (1): 14–7. DOI: 10.1159/000210098
41. Плотникова Е.Ю., Краснова М.В., Краснов К.А., Баранова Е.Н. Ларингофарингеальный рефлюкс в гастроэнтерологической практике. Лечащий врач. 2014; 2: 61–5. https://elibrary.ru/item.asp?id=21160628
[Plotnikova E.Iu., Krasnova M.V., Krasnov K.A., Baranova E.N. Laryngopharyngeal reflux in gastroenterological practice. Attending doctor. 2014; 2: 61–5. https://elibrary.ru/item.asp?id=21160628 (in Russian).]
42. Lechien JR, Allen JE, Barillari MR et al. Management of Laryngopharyngeal Reflux Around the World: An International Study. Laryngoscope 2020. DOI: 10.1002/lary.29270
43. Анготоева И.Б., Мушьян И.А. Боль в горле и ее причины. Российская оториноларингология. 2019; 3: 17–21. DOI: 10.18692/1810-4800-2019-3-17-21
[Angotoeva I.B., Mush’yan I.A. Sore throat and its causes. Russian Otorhinolaryngology. 2019; 3: 17–21. DOI: 10.18692/1810-4800-2019-3-17-21 (in Russian).]
44. Bove MJ, Rosen C. Diagnosis and management of laryngoрharyngeal reflux disease. Curr Opin Otolaryngol Head Neck Surg 2006; 14: 116–23. DOI: 10.1097/01.moo.0000193177.62074.fd
45. Wong MW, Bair MJ, Chang WC et al. Clinical and psychological characteristics in gastroesophageal reflux disease patients overlapping with laryngopharyngeal reflux symptoms. J Gastroenterol Hepatol 2019; 34 (10): 1720–6. DOI: 10.1111/jgh.14651 
46. Маев И.В., Сельская Ю.В., Андреев Д.Н. и др. Ларингофарингеальный рефлюкс: клиническое значение, современные подходы к диагностике и лечению. Медицинский совет. 2019; 3: 8–16. DOI: 10.21518/2079-701X-2019-3-8-16
[Maev I.V., Selskaya Y.V., Andreev D.N. et al. Laryngopharyngeal reflux: clinical significance, modern approaches to diagnosis and treatment. Medical Counsil. 2019; 3: 8–16. DOI: 10.21518/2079-701X-2019-3-8-16 (in Russian).]
47. Ford CN. Evaluation and management of laryngopharyngeal reflux. JAMA 2005; 294 (12): 1534–40. DOI: 10.1001/jama.294.12.1534
48. Gelardi M, Ciprandi G. Focus on gastroesophageal reflux (GER) and laryngopharyngeal reflux (LPR): new pragmatic insights in clinical practice. J Biol Regul Homeost Agents 2018; 32 (1 Suppl. 2): 41–7. https://pubmed.ncbi.nlm.nih.gov/29436209/
49. Старостина С.В., Махов В.М., Большаков А.В. Роль функционально-анатомических нарушений пищевода и желудка в развитии патологии гортани: обзорная статья. Consilium Medicum. 2019; 21 (11): 9–14. DOI: 10.26442/20751753.2019.11.190637
[Starostina S.V., Мakhov V.M., Bolshakov A.V. The role of functional and anatomical disorders of the esophagus and stomach in the development of laryngeal pathology: review article. Consilium Medicum. 2019; 21 (11): 9–14. DOI: 10.26442/20751753.2019.11.190637 (in Russian).]
50. Старостина С.В., Махов В.М., Сторонова О.А. и др. Возможности 24-часовой pН-импедансометрии пищевода в диагностике ГЭРБ-ассоциированных заболеваний гортани. Медицинский совет. 2020; 16: 62–72. DOI: 10.21518/2079-701X-2020-16-62-72
[Starostina S.V., Makhov V.M., Storonova O.A. et al. Сapabilitу of 24-hour esophageal pH-impedance monitoring in the diagnosis of GERD-associated laryngeal diseases. Medical Council 2020; 16: 62–72. DOI: 10.21518/2079-701X-2020-16-62-72 (in Russian).]
51. Trudgill NJ, Sifrim D, Sweis R et al. British Society of Gastroenterology guidelines for oesophageal manometry and oesophageal reflux monitoring. Gut 2019; 66: 1–20. DOI: 10.1136/ gutjnl-2018-318115
52. Patterson N, Mainie I, Rafferty G et al. Nonacid reflux episodes reaching the pharynx are important factors associated with cough. J Clin Gastroenterol 2009; 43: 414–9. DOI: 10.1097/MCG.0b013e31818859a3
53. Wang AJ, Liang MJ, Jiang AY et al. Gastroesophageal and laryngopharyngeal reflux detected by 24-hour combined impedance and pH monitoring in healthy Chinese volunteers. J Dig Dis 2011; 12: 173–80. DOI: 10.1111/j.1751-2980.2011.00502.x 
54. Lechien JR, Saussez S, Muls V et al. Laryngopharyngeal Reflux: A State-of-the-Art Algorithm Management for Primary Care Physicians. J Clin Med 2020; 9 (11): E3618. DOI: 10.3390/jcm9113618
55. Hayat JO, Gabieta-Somnez S, Yazaki E et al. Pepsin in saliva for the diagnosis of gastro oesophageal reflux disease. Gut 2015; 64: 373–80. DOI: 10.1136/gutjnl-2014-307049 
56. El-Serag H, Becher A, Jones R. Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies. Aliment Pharmacol Ther 2010; 32 (6): 720–37. DOI: 10.1111/j.1365-2036.2010.04406.x
57. Lechien JR, Mouawad F, Barillari MR et al. Treatment of laryngopharyngeal reflux disease: A systematic review. World J Clin Cases. 2019; 7 (19): 2995–3011. DOI: 10.12998/wjcc.v7.i19.2995
58. Liu C, Wang H, Liu K. Meta-analysis of the efficacy of proton pump inhibitors for the symptoms of laryngopharyngeal reflux. Braz J Med Biol Res 2016; 49 (7): e5149. DOI: 10.1590/1414-431X20165149
59. Brodsky L, Carr MM. Extraesophageal reflux in children. Curr Opin Otolaryngol Head Neck Surg 2006; 14 (6): 387–92. DOI: 10.1097/MOO.0b013e3280106326
60. Lechien JR, Bock JM, Carroll TL, Akst LM. Is empirical treatment a reasonable strategy for laryngopharyngeal reflux? A contemporary review. Clin Otolaryngol 2020; 45 (4): 450–8. DOI: 10.1111/coa.13518 
61. Анготоева И.Б., Лоранская И.Д., Косяков С.Я., Карева Е.Н. Ларингофарингеальный рефлюкс: персонифицированный подход к лечению. Эксперим. и клин. фармакология. 2019; 82 (3): 7–12. DOI: 10.30906/0869-2092-2019-82-3-7-12
[Angotoeva I.B., Loranskaia I.D., Kosiakov S.Ia., Kareva E.N. Proton Pump Inhibitors for Personified Treatment of Laryngopharyngeal Reflux Patients without Symptoms of Gastroesophageal Disease. Exp Clin Pharmacol. 2019; 82 (3): 7–12. DOI: 10.30906/0869-2092-2019-82-3-7-12 (in Russian).]
62. Haastrup PF, Thompson W, Søndergaard J, Jarbøl DE. Side Effects of Long-Term Proton Pump Inhibitor Use: A Review. Basic Clin Pharmacol Toxicol 2018; 123 (2): 114–21. DOI: 10.1111/bcpt.13023
63. Schubert ML. Adverse effects of proton pump inhibitors: fact or fake news? Curr Opin Gastroenterol 2018; 34 (6): 451–7. DOI: 10.1097/ MOG.0000000000000471
64. Song TJ, Kim J. Risk of post-stroke pneumonia with proton pump inhibitors, H2 receptor antagonists and mucoprotective agents: A retrospective nationwide cohort study. PLoS One 2019; 14 (5): e0216750. DOI: 10.1371/ journal.pone.0216750
65. Makunts T, Cohen IV, Awdishu L, Abagyan R. Analysis of postmarketing safety data for proton-pump inhibitors reveals increased propensity for renal injury, electrolyte abnormalities, and nephrolithiasis. Sci Rep 2019; 9 (1): 2282. DOI: 10.1038/s41598-019-39335-7
66. Yuan J, He O, Nguyen LH et al. Regular use of proton pump inhibitors and risk of type 2 diabetes: results from three prospective cohort studies. Gut 2020. DOI: 10.1136/gutjnl-2020-322557
67. Zirk-Sadowski J, Masoli JA, Delgado J et al. Proton-Pump Inhibitors and Long-Term Risk of Community-Acquired Pneumonia in Older Adults. J Am Geriatr Soc 2018; 66 (7): 1332–8. DOI: 10.1111/jgs.15385 
68. Ble A, Zirk-Sadowski J, Masoli JA. Reply to: Proton Pump Inhibitors and Long-term Risk of Community-acquired Pneumonia in Older Adults. J Am Geriatr Soc 2018; 66 (12): 2428–9. DOI: 10.1111/jgs.15637 
69. Almario CV, Chey WD, Spiegel BMR. Increased Risk of COVID-19 Among Users of Proton Pump Inhibitors. Am J Gastroenterol 2020; 115 (10): 1707–15. DOI: 10.14309/ajg.0000000000000798 
70. Karkos PD, Wilson JA. The diagnosis and management of globus pharyngeus: our perspective from the United Kingdom. Curr Opin Otolaryngol Head Neck Surg 2008; 16 (6): 521–4. DOI: 10.1097/MOO.0b013e328316933b
71. McGlashan JA, Johnstone LM, Sykes J et al. The value of a liquid alginate suspension (Gaviscon Advance) in the management of laryngopharyngeal reflux. Eur Arch Otorhinolaryngol 2009; 266 (2): 243–51. DOI: 10.1007/s00405-008-0708-7 
72. Wilkie MD, Fraser HM, Raja H. Gaviscon Advance alone versus co-prescription of Gaviscon Advance and proton pump inhibitors in the treatment of laryngopharyngeal reflux. Eur Arch Otorhinolaryngol 2018; 275 (10): 2515–21. DOI: 10.1007/s00405-018-5079-0
73. Sun J, Yang C, Zhao H et al. Randomised clinical trial: the clinical efficacy and safety of an alginate-antacid (Gaviscon Double Action) versus placebo, for decreasing upper gastrointestinal symptoms in symptomatic gastroesophageal reflux disease (GERD) in China. Aliment Pharmacol Ther 2015; 42 (7): 845–54. DOI: 10.1111/apt.13334
74. Gelardi M, Ciprandi G. Focus on gastroesophageal reflux (GER) and laryngopharyngeal reflux (LPR): new pragmatic insights in clinical practice. J Biol Regul Homeost Agents 2018; 32 (1 Suppl. 2): 41–7.
75. Lechien JR, Bobin F, Muls V et al. Gastroesophageal reflux in laryngopharyngeal reflux patients: Clinical features and therapeutic response. Laryngoscope 2020; 130 (8): E479–89. DOI: 10.1002/lary.28482
76. Lieder A, Issing W. Treatment for resilient cough owing to laryngopharyngeal reflux with a combination of proton pump inhibitor and Gaviscon Advance: how we do it. Clin Otolaryngol 2011; 36 (6): 583–7. DOI: 10.1111/j.1749-4486.2011.02394.x
77. Coyle C, Crawford G, Wilkinson J et al. Randomised clinical trial: addition of alginate-antacid (Gaviscon Double Action) to proton pump inhibitor therapy in patients with breakthrough symptoms. Aliment Pharmacol Ther 2017; 45 (12): 1524–33. DOI: 10.1111/apt.14064
78. Hampson FC, Farndale A, Strugala V et al. Alginate rafts and their characterisation. Int J Pharm 2005; 294: 137–47. DOI: 10.1016/j.ijpharm.2005.01.036
79. Tran T, Lowry A, El-Serag H. Meta-analysis: the efficacy of over-the-counter gastro-oesophageal reflux disease drugs. Aliment Pharmacol Ther 2007; 25 (2): 143–53. DOI: 10.1111/j.1365-2036.2006.03135.x
80. Hampson FC, Jolliffe IG, Bakhtyari A et al. Alginate-antacid combinations: raft formation and gastric retention studies. Drug Dev Ind Pharm 2010; 36: 614–23. DOI: 10.3109/03639040903388290
81. Успенский Ю.П., Барышникова Н.В., Белоусова Л.Н. Использование альгинатов при разных вариантах изжоги. Consilium Medicum. 2014; 2: 43–6. http://elibrary.ru/item.asp?id=22824128
[Uspenskii Iu.P., Baryshnikova N.V., Belousova L.N. Use of alginates for different types of heartburn. Consilium Medicum. 2014; 2: 43–6. http://elibrary.ru/item.asp?id=22824128 (in Russian).]
82. Kwiatek MA, Roman S, Fareeduddin A et al. An alginate-antacid formulation (Gaviscon Double Action Liquid) can eliminate or displace the postprandial ‘acid pocket’ in symptomatic GERD patients. Aliment Pharmacol Ther 2011; 34: 59–66. DOI: 10.1111/j.1365-2036.2011.04678.x
83. Dettmar PW, Hampson FC, Taubel J et al. The suppression of gastro-oesophageal reflux by alginates. Int J Clin Pract. 2007; 61 (10): 1654–62. DOI: 10.1111/j.1742- 1241.2007.01524.x
84. Деттмар У., Хэмпсон Ф.Ч., Тоубел Д. и др. Подавление гастроэзофагеального рефлюкса при помощи альгинатов. Рус. мед. журн. 2008; 2: 83–6. https://gastroscan.ru/literature/authors/2549
[Dettmar PW, Hampson FC, Taubel J. The suppression of gastro-oesophageal reflux by alginates. The suppression of gastro-oesophageal reflux by alginates. Int J Clin Pract 2007; 61 (10): 1654–62 (in Russian).]
85. Thomas E, Wade A, Crawford G et al. Randomised clinical trial: relief of upper gastrointestinal symptoms by an acid pocket-targeting alginate-antacid (Gaviscon Double Action) – a double-blind, placebo-controlled, pilot study in gastrooesophageal reflux disease. Aliment Pharmacol Ther 2014; 39: 595–602. DOI: 10.1111/apt.12640
86. Uzan M, Uzan S, Sureau C, Richard-Berthe C. Heartburn and regurgitation in pregnancy. Efficacy and innocuousness of treatment with Gaviscon suspension. Revue Francaise de Gynecologie et d’Obstetrique 1988; 83 (7–9): 569–72. https://pubmed.ncbi.nlm.nih.gov/2848305/
87. Hutt HJ, Tauber O, Flach D. Gaviscon in the treatment of reflux disease. Results of an observational study. Fortschritte der Medizin 1990; 108: 598–600. https://pubmed.ncbi.nlm.nih.gov/2258131/
88. Lindow SW, Regnéll P, Sykes J, Little S. An open-label, multicentre study to assess the safety and efficacy of a novel reflux suppressant (Gaviscon Advance) in the treatment of heartburn during pregnancy. Int J Clin Pract 2003; 57 (3): 175–9. https://pubmed.ncbi.nlm.nih.gov/12723718/
89. Strugala V, Bassin J, Swales VS et al. Assessment of the Safety and Efficacy of a Raft-Forming Alginate Reflux Suppressant (Liquid Gaviscon) for the Treatment of Heartburn during Pregnancy. ISRN Obstet Gynecol 2012; 2012: 481870. DOI: 10.5402/2012/481870
90. Васильев Ю.В. Гевискон как производное альгинатов в терапии гастроэзофагеальной рефлюксной болезни. Рус. мед. журн. 2012; 5: 800–2. https://www.elibrary.ru/item.asp?id=17854506
[Vasil'ev Iu.V. Geviskon kak proizvodnoe al'ginatov v terapii gastroezofageal'noi refliuksnoi bolezni. RMJ. 2012; 5: 800–2. https://www.elibrary.ru/item.asp?id=17854506 (in Russian).]
91. Бутов М., Масленникова Е., Кузнецов П. Альгинат гевискон форте в лечении гастроэзофагеальной рефлюксной болезни. Врач. 2009; 5: 73–5. https://www.elibrary.ru/item.asp?id=12415698
[Butov M., Maslennikova E., Kuznetsov P. Geviscon alginate forte in the treatment of gastroesophageal reflux disease. Doctor. 2009; 5: 73–5. https://www.elibrary.ru/item.asp?id=12415698 (in Russian).]
92. Онучина Е.В., Брикова С.И., Цуканов В.В. Использование препарата гевискон для купирования симптоматики пищеводных, внепищеводных синдромов и функциональной диспепсии у больных ГЭРБ пожилого и старческого возраста. Эксперим. и клин. гастроэнтерология. 2010; 10: 80–6. https://www.elibrary.ru/item.asp?id=15247112
[Onuchina E.V., Brikova S.I., Tsukanov V.V. Ispol'zovanie preparata geviskon dlia kupirovaniia simptomatiki pishchevodnykh, vnepishchevodnykh sindromov i funktsional'noi dispepsii u bol'nykh GERB pozhilogo i starcheskogo vozrasta. Exp Clin Gastroenterol. 2010; 10: 80–6. https://www.elibrary.ru/item.asp?id=15247112 (in Russian).]
93. Пахомова И.Г., Успенский Ю.П., Павлова Е.Ю. Перспективы использования препарата гевискон форте в лечении гастроэзофагеальной рефлюксной болезни и НПВП-индуцированных поражений пищевода. Consilium Medicum. 2011; 2: 13–7. https://www.elibrary.ru/item.asp?id=21256356
[Pakhomova I.G., Uspenskii Iu.P., Pavlova E.Iu. Prospects for the use of Gaviscon forte in the treatment of gastroesophageal reflux disease and NSAID-induced lesions of the esophagus. Consilium Medicum. 2011; 2: 13–7. https://www.elibrary.ru/item.asp?id=21256356 (in Russian).]
94. Звенигородская Л.А., Чурикова А.А. Особенности терапии гастроэзофагеальной рефлюксной болезни при ишемической болезни сердца. Эффективная фармакотерапия. 2012; 27: 22–7. https://www.elibrary.ru/item.asp?id=21807065
[Zvenigorodskaia L.A., Churikova A.A. Osobennosti terapii gastroezofageal'noi refliuksnoi bolezni pri ishemicheskoi bolezni serdtsa. Effect Pharmacother. 2012; 27: 22–7. https://www.elibrary.ru/item.asp?id=21807065 (in Russian).]
95. Булгаков С.А. Гевискон при изжоге, обусловленной гастроэзофагеальной рефлюксной болезнью (ГЭРБ). Фарматека. 2011; 20: 54–8. https://www.elibrary.ru/item.asp?id=17271340
[Bulgakov S.A. Gaviscon for the treatment of heartburn attributable to gastroesophageal reflux disease. Farmateka. 2011; 20: 54–8. https://www.elibrary.ru/item.asp?id=17271340 (in Russian).]
96. Калягин А.Н., Аснер Т.В. Гевискон в ведении больных с внепищеводными проявлениями гастроэзофагеальной рефлюксной болезни. Consilium Medicum. 2013; 1: 14–7. https://www.elibrary.ru/item.asp?id=21256395
[Kaliagin A.N., Asner T.V. Gaviscon in the management of patients with extraesophageal manifestations of gastroesophageal reflux disease.  Consilium Medicum. 2013; 1: 14–7. https://www.elibrary.ru/
item.asp?id=21256395 (in Russian).]
97. Гришечкина И.А., Лисняк М.В., Трухан Д.И. и др. Симптомы гастроэзофагеальной рефлюксной болезни и беременнность. Международный журнал экспериментального образования. 2015; 7: 152–53. https://elibrary.ru/item.asp?id=23488979
[Grishechkina I.A., Lisniak M.V., Trukhan D.I. et al. Simptomy gastroezofageal'noi refliuksnoi bolezni i beremennnost. Int J Exp Edu. 2015; 7: 152–53. https://elibrary.ru/item.asp?id=23488979 (in Russian).]
98. Аникин Г.С. Место альгинатов в лечении гастроэзофагеальной рефлюксной болезни. Consilium Medicum. 2015; 1: 36–8. https://www.elibrary.ru/item.asp?id=23454653
[Anikin G.S. The role of alginates in the treatment of gastroesophageal reflux disease. Gastroenterology. Consilium Medicum. 2015; 1: 36–8. https://www.elibrary.ru/item.asp?id=23454653 (in Russian).]
99. Трухан Д.И., Гришечкина И.А. Терапия изжоги беременных: фокус на альгинаты. Consilium Medicum. 2016; 6: 29–34. https://www.elibrary.ru/item.asp?id=27348305
[Trukhan D.I., Grishechkina I.A. Heartburn pregnant therapy: focus on alginate. Consilium Medicum. 2016; 6: 29–34. https://www.elibrary.ru/item.asp?id=27348305 (in Russian).]
100. Пахомова И.Г., Зиновьева Е.Н. Гастроэзофагеальная рефлюксная болезнь у полиморбидного пациента: особенности терапии. РМЖ. 2017; 10: 760–4. https://www.elibrary.ru/
item.asp?id=30282554
[Pakhomova I.G., Zinovieva E.N. Gastroesophageal reflux disease in a polymorbid patient: features of therapy. RMZh. 2017; 10: 760–4. https://www.elibrary.ru/item.asp?id=30282554 (in Russian).]
101. Rohof WO, Bennink RJ, Smout AJ et al. An alginate-antacid formulation localizes to the acid pocket to reduce acid reflux in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2013; 11 (12): 1585–91. DOI: 10.1016/j.cgh.2013.04.046

________________________________________________

1. Dent J, Brun J, Fendrick A et al. An evidence-based appraisal of reflux disease management – the Genval Workshop Report. Gut 1999; 44 (Suppl. 2): S1–16. DOI: 10.1136/gut.44.2008.s1
2. Ivashkin V.T., Maev I.V., Trukhmanov A.S. et al. Recommendations of the Russian Gastroenterological Association in Diagnosis and Treatment of Gastroesophageal Reflux Disease. Rus J Gastroenterol Hepatol Coloproctol. 2020; 30 (4): 70–97. DOI: 10.22416/1382-4376-2020-30-4-70-97 (in Russian).
3. Vakil N, van Zanten SV, Kahrilas P et al. Montreal definition and classification of gastroesophageal reflux disease: a global evidence – based consensus. Am J Gastroenterol 2006; 101 (8): 1900–20. https://www.unboundmedicine.com/medline/citation/16928254/The_Montreal_definition_and_classification...
4. Global Practical Guidelines of the World Gastroenterological Organization. GERD. 
http://www.worldgastroenterology.org/guidelines/global-guidelines/gastroesophageal-reflux-disease/ga... (in Russian).
5. Trukhan D.I., Tarasova L.V. Gastroesophageal reflux disease practice of the first contact doctor. Rus Med News. 2013; 1: 16–25. 
https://www.gastroscan.ru/literature/authors/6875 (in Russian).
6. Trukhan D.I., Filimonov S.N. Differential diagnosis of major gastroenterological syndromes and symptoms. Moscow: Practical medicine, 2016. 
https://www.litres.ru/dmitriy-truhan/differencialnyy-diagnoz-osnovnyh-gastroenterologic-57081630/ (in Russian).
7. Tarasova L.V., Trukhan D.I. Heartburnpresent-day aspects of differential diagnostics and treatment. Med Almanac. 2013; 1: 91–5. https://elibrary.ru/item.asp?id=18910551 (in Russian).
8. Trukhan D.I., Tarasova L.V. Diagnostic and therapeutic tactics of general practitioner with heartburn. J Family Med. 2013; 4: 19–26. https://www.elibrary.ru/item.asp?id=20469510 (in Russian).
9. Trukhan D.I. Diagnostic and treatment policy with heartburn at the stage of primary health care. Consilium Medicum. 2016; 18 (1): 17–22. https://www.elibrary.ru/item.asp?id=26211004 (in Russian).
10. Trukhan D.I., Viktorova I.A. Gastroesophageal reflux disease: actual aspects of diagnostics and treatment in real clinical practice of therapist. Medical Council. 2019; 14: 22–31. DOI: 10.21518/2079-701X-2019-14-22-31 (in Russian).
11. Grishechkina I.A., Trukhan D.I. The role of psychovegetative status and serotonergic system in patients with gastroesophageal reflux disease. Exp Clin Gastroenterol. 2014; 9 (109): 48–51. https://elibrary.ru/item.asp?id=22677293 (in Russian).
12. Trukhan D.I., Grishechkina I.A. Actual aspects of anti-secretor therapy of gastroesophageal reflux disease. Medical Council. 2017; 15: 28–35. DOI: 10.21518/2079-701X-2017-15-28-35 (in Russian).
13. Mayev I.V., Yurenev G.L., Dicheva D.T. et al. Pulmonary mask of gastroesophageal reflux disease. Consilium Medicum. 2012; 14 (1): 15–8.
https://con-med.ru/magazines/gastroenterology/gastroenterology-01-2012/pulmonologicheskaya_maska_gas... (in Russian).]
14. Trukhan L.Yu., Trukhan D.I., Viktorova I.A. Changes in the organs and tissues of the oral cavity with diseases of the internal organs. Handbook for Practitioners Doctors. 2011; 7: 8–14. https://elibrary.ru/item.asp?id=23605228 (in Russian).
15. Ivashkin V.T., Maev I.V., Truhmanov A.S., Rumntseva D.E. Modern achievements in the diagnosis and treatment of the refractory gastroesophageal reflux disease. Therapeutic Archive. 2018; 90 (8): 4–12. DOI: 10.26442/terarkh20189084-12 (in Russian).
16. Trukhan D.I., Goloshubina V.V., Trukhan L.Yu. Changes in the organs and tissues of the oral cavity with digestive system diseases. Exp Clin Gastroenterol. 2015; 3 (115): 90–3. https://cyberleninka.ru/article/n/izmeneniya-so-storony-organov-i-tkaney-polosti-rta-pri-gastroenter... (in Russian).
17. Yurenev G.L., Samsonov A.A., Yureneva-Tkhorzhevskaya T.V. Modern look at cardiac manifestations of gastroesophageal reflux disease. Consilium Medicum. 2015; 17 (12): 44–9. DOI: 10.26442/2075-1753_2015.12.44-49 (in Russian).
18. Yurenev G.L., Samsonov A.A., Yureneva-Tkhorzhevskaya T.V., Maev I.V. Bronchoobstructive syndrome in patients with gastroesophageal reflux disease: extraesophageal manifestations of the disease or bronchial asthma? Consilium Medicum. 2014; 16 (2): 33–38. https://www.elibrary.ru/item.asp?id=21994300 (in Russian).
19. Maev I.V., Yurenev G. L., Yureneva-Tkhorzhevskaya T.V. Clinical significance of heart rhythm variability in patients with gastroesophageal reflux disease. Clin Med. 2016; 8: 574–82. DOI: 10.18821/0023-2149-2016-94-8-574-582 (in Russian).
20. Trukhan L.Yu., Trukhan D.I. Stomatoligical problems of gastroenterological patients and their possible solutions. Medical Council. 2016; 19: 134–7. DOI: 10.21518/2079-701X-2016-19-134-137 (in Russian).
21. Jaspersen D, Kulig M, Labenz J et al. Prevalence of extraoesophageal manifestations in gastro-oesophageal reflux disease: an analysis based on the ProGERD Study. Aliment Pharmacol Ther 2003; 17: 1515–20. DOI: 10.1046/j.1365- 2036.2003.01606.x
22. Bayliss EA, Steiner JF, Fernald DH et al. Descriptions of barriers to self-care by persons with comorbid chronic diseases. Ann Fam Med 2003; 1 (1): 15–21. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1466563/
23. Hughes LD, McMurdo ME, Guthrie B. Guidelines for people not for diseases: the challenges of applying UK clinical guidelines to people with multimorbidity. Age Ageing 2013; 42 (1): 62–9. DOI: 10.1093/ageing/afs100 
24. Ferrer A, Formiga F, Sanz H et al. Multimorbidity as specific disease combinations, an important predictor factor for mortality in octogenarians: the Octabaix study. Clin Interv Aging 2017; 12: 223–31. DOI: 10.2147/CIA.S123173. 
25. Trukhan D.I., Konshu N.V. Rational pharmacotherapy in the clinic of internal diseases through the prism of multimorbidity and drug safety.  Handbook for Practitioners Doctors. 2019; (2): 10–8. https://www.elibrary.ru/item.asp?id=44162870 (in Russian).
26. Trukhan D.I., Tarasova L.V. The clinical symptoms, diagnostics and treatment of chronic duodenitis. Exp Clin Gastroenterol. 2012; 11: 104–14. https://elibrary.ru/item.asp?id=21589957 (in Russian).
27. Khlynova O.V., Tuev A.V., Beresneva L.N., Agafonov A.V. The problem of concomitant diseases with a focus on the cardiovascular system condition in patients with arterial hypertension and acid-related diseases. Kazan Med J. 2013; 1: 80–5. https://elibrary.ru/item.asp?id=18794502 (in Russian).
28. Trukhan D.I., Tarasova L.V., Trukhan L.Y. Gastroenterological disorders of patients with diabetes mellitus. J Family Med. 2013; 8: 51–9. https://www.elibrary.ru/item.asp?id=20469561 (in Russian).
29. Trukhan D.I., Goloshubina V.V., Trukhan L.Yu.  Changes in the upper gastrointestinal tract in patients with diabetes mellitus: topical issues of diagnosis, treatment and control.  Handbook for Practitioners Doctors. 2014; 11: 40–3. https://www.elibrary.ru/item.asp?id=23417344 (in Russian).
30. Yurenev G.L., Kazyulin A.N., Yureneva-Tkhorzhevskaya T.V. The influence of acid-suppressive therapy on the clinical course of ischemic heart disease with refractory pain syndrome in the chest. Therapy. 2015; 2: 28–36. https://elibrary.ru/item.asp?id=25471414 (In Russ.)
31. Burkov S.G., Kasimtseva E.V., Agafonova L.Yu. State of the upper digestive tract and rational choice of antisecretory therapy in elderly patients. Farmateka. 2015; 2: 56–61. https://pharmateca.ru/ru/archive/article/30798 (in Russian).
32. Yurenev G.L., Mironova E.M., Andreev D.N., Yureneva-Thorzhevskaya T.V. Clinical and pathogenetic parallels gastroesophageal reflux disease and obesity. Farmateka. 2017; 13: 30–9. https://www.gastroscan.ru/literature/authors/9856 (in Russian).
33. Shcherbenkov I.M., Staseva I.V. Multimorbid patient: gastro-esophageal reflux disease in focus. Consilium Medicum. 2018; 20 (8): 24–31. DOI: 10.26442/2075-1753_2018.8.24-31 (in Russian).
34. Koufman JA. The otolaryngologic manifestations of gastroesophageal reflux disease (GERD): a clinical investigation of 225 patients using ambulatory 24-hour pH monitoring and an experimental investigation of the role of acid and pepsin in the development of laryngeal injury. Laryngoscope 1991; 101 (Suppl. 53): 1–78. DOI: 10.1002/lary.1991.101.s53.1
35. Koufman JA, Aviv JE, Casiano RR, Shaw GY. Laryngopharyngeal reflux: Position statement of the Committee on Speech, Voice, and Swallowing Disorders of the American Academy of Otolaryngology–Head and Neck Surgery. Otolaryngol Head Neck Surg 2002; 127 (1): 32–5. DOI: 10.1067/mhn.2002.125760
36. Angotoeva I.B., Muldasheva A.A. Current views on the problem of laryngopharyngeal reflux. Medical Council. 2015; 15: 44–9. https://elibrary.ru/item.asp?id=25319236 (in Russian).
37. Yaravy I. Yu., Nidelko A.A., Bycel A.G. Laryngopharyngeal reflux. Medical J. 2015; 3: 29–34. https://elibrary.ru/item.asp?id=24251748 (in Russian).
38. Lechien JR, Saussez S, Karkos PD. Laryngopharyngeal reflux disease: clinical presentation, diagnosis and therapeutic challenges in 2018. Curr Opin Otolaryngol Head Neck Surg 2018; 26 (6): 392–402. DOI: 10.1097/MOO.0000000000000486
39. Lechien JR, Akst LM, Hamdan AL et al. Evaluation and Management of Laryngopharyngeal Reflux Disease: State of the Art Review. Otolaryngol Head Neck Surg 2019; 160 (5): 762–82. DOI: 10.1177/0194599819827488
40. Hammer HF. Reflux-associated laryngitis and laryngopharyngeal reflux: a gastroenterologist's point of view. Dig Dis 2009; 27 (1): 14–7. DOI: 10.1159/000210098
41. Plotnikova E.Iu., Krasnova M.V., Krasnov K.A., Baranova E.N. Laryngopharyngeal reflux in gastroenterological practice. Attending doctor. 2014; 2: 61–5. 
https://elibrary.ru/item.asp?id=21160628 (in Russian).
42. Lechien JR, Allen JE, Barillari MR et al. Management of Laryngopharyngeal Reflux Around the World: An International Study. Laryngoscope 2020. DOI: 10.1002/lary.29270
43. Angotoeva I.B., Mush’yan I.A. Sore throat and its causes. Russian Otorhinolaryngology. 2019; 3: 17–21. DOI: 10.18692/1810-4800-2019-3-17-21 (in Russian).
44. Bove MJ, Rosen C. Diagnosis and management of laryngoрharyngeal reflux disease. Curr Opin Otolaryngol Head Neck Surg 2006; 14: 116–23. DOI: 10.1097/01.moo.0000193177.62074.fd
45. Wong MW, Bair MJ, Chang WC et al. Clinical and psychological characteristics in gastroesophageal reflux disease patients overlapping with laryngopharyngeal reflux symptoms. J Gastroenterol Hepatol 2019; 34 (10): 1720–6. DOI: 10.1111/jgh.14651 
46. Maev I.V., Selskaya Y.V., Andreev D.N. et al. Laryngopharyngeal reflux: clinical significance, modern approaches to diagnosis and treatment. Medical Counsil. 2019; 3: 8–16. DOI: 10.21518/2079-701X-2019-3-8-16 (in Russian).
47. Ford CN. Evaluation and management of laryngopharyngeal reflux. JAMA 2005; 294 (12): 1534–40. DOI: 10.1001/jama.294.12.1534
48. Gelardi M, Ciprandi G. Focus on gastroesophageal reflux (GER) and laryngopharyngeal reflux (LPR): new pragmatic insights in clinical practice. J Biol Regul Homeost Agents 2018; 32 (1 Suppl. 2): 41–7. https://pubmed.ncbi.nlm.nih.gov/29436209/
49. Starostina S.V., Мakhov V.M., Bolshakov A.V. The role of functional and anatomical disorders of the esophagus and stomach in the development of laryngeal pathology: review article. Consilium Medicum. 2019; 21 (11): 9–14.
DOI: 10.26442/20751753.2019.11.190637 (in Russian).
50. Starostina S.V., Makhov V.M., Storonova O.A. et al. Сapabilitу of 24-hour esophageal pH-impedance monitoring in the diagnosis of GERD-associated laryngeal diseases. Medical Council 2020; 16: 62–72. DOI: 10.21518/2079-701X-2020-16-62-72 (in Russian).
51. Trudgill NJ, Sifrim D, Sweis R et al. British Society of Gastroenterology guidelines for oesophageal manometry and oesophageal reflux monitoring. Gut 2019; 66: 1–20. DOI: 10.1136/ gutjnl-2018-318115
52. Patterson N, Mainie I, Rafferty G et al. Nonacid reflux episodes reaching the pharynx are important factors associated with cough. J Clin Gastroenterol 2009; 43: 414–9. DOI: 10.1097/MCG.0b013e31818859a3
53. Wang AJ, Liang MJ, Jiang AY et al. Gastroesophageal and laryngopharyngeal reflux detected by 24-hour combined impedance and pH monitoring in healthy Chinese volunteers. J Dig Dis 2011; 12: 173–80. DOI: 10.1111/j.1751-2980.2011.00502.x 
54. Lechien JR, Saussez S, Muls V et al. Laryngopharyngeal Reflux: A State-of-the-Art Algorithm Management for Primary Care Physicians. J Clin Med 2020; 9 (11): E3618. DOI: 10.3390/jcm9113618
55. Hayat JO, Gabieta-Somnez S, Yazaki E et al. Pepsin in saliva for the diagnosis of gastro oesophageal reflux disease. Gut 2015; 64: 373–80. DOI: 10.1136/gutjnl-2014-307049 
56. El-Serag H, Becher A, Jones R. Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies. Aliment Pharmacol Ther 2010; 32 (6): 720–37. DOI: 10.1111/j.1365-2036.2010.04406.x
57. Lechien JR, Mouawad F, Barillari MR et al. Treatment of laryngopharyngeal reflux disease: A systematic review. World J Clin Cases. 2019; 7 (19): 2995–3011. DOI: 10.12998/wjcc.v7.i19.2995
58. Liu C, Wang H, Liu K. Meta-analysis of the efficacy of proton pump inhibitors for the symptoms of laryngopharyngeal reflux. Braz J Med Biol Res 2016; 49 (7): e5149. DOI: 10.1590/1414-431X20165149
59. Brodsky L, Carr MM. Extraesophageal reflux in children. Curr Opin Otolaryngol Head Neck Surg 2006; 14 (6): 387–92. DOI: 10.1097/MOO.0b013e3280106326
60. Lechien JR, Bock JM, Carroll TL, Akst LM. Is empirical treatment a reasonable strategy for laryngopharyngeal reflux? A contemporary review. Clin Otolaryngol 2020; 45 (4): 450–8. DOI: 10.1111/coa.13518 
61. Angotoeva I.B., Loranskaia I.D., Kosiakov S.Ia., Kareva E.N. Proton Pump Inhibitors for Personified Treatment of Laryngopharyngeal Reflux Patients without Symptoms of Gastroesophageal Disease. Exp Clin Pharmacol. 2019; 82 (3): 7–12. DOI: 10.30906/0869-2092-2019-82-3-7-12 (in Russian).
62. Haastrup PF, Thompson W, Søndergaard J, Jarbøl DE. Side Effects of Long-Term Proton Pump Inhibitor Use: A Review. Basic Clin Pharmacol Toxicol 2018; 123 (2): 114–21. DOI: 10.1111/bcpt.13023
63. Schubert ML. Adverse effects of proton pump inhibitors: fact or fake news? Curr Opin Gastroenterol 2018; 34 (6): 451–7. DOI: 10.1097/ MOG.0000000000000471
64. Song TJ, Kim J. Risk of post-stroke pneumonia with proton pump inhibitors, H2 receptor antagonists and mucoprotective agents: A retrospective nationwide cohort study. PLoS One 2019; 14 (5): e0216750. DOI: 10.1371/ journal.pone.0216750
65. Makunts T, Cohen IV, Awdishu L, Abagyan R. Analysis of postmarketing safety data for proton-pump inhibitors reveals increased propensity for renal injury, electrolyte abnormalities, and nephrolithiasis. Sci Rep 2019; 9 (1): 2282. DOI: 10.1038/s41598-019-39335-7
66. Yuan J, He O, Nguyen LH et al. Regular use of proton pump inhibitors and risk of type 2 diabetes: results from three prospective cohort studies. Gut 2020. DOI: 10.1136/gutjnl-2020-322557
67. Zirk-Sadowski J, Masoli JA, Delgado J et al. Proton-Pump Inhibitors and Long-Term Risk of Community-Acquired Pneumonia in Older Adults. J Am Geriatr Soc 2018; 66 (7): 1332–8. DOI: 10.1111/jgs.15385 
68. Ble A, Zirk-Sadowski J, Masoli JA. Reply to: Proton Pump Inhibitors and Long-term Risk of Community-acquired Pneumonia in Older Adults. J Am Geriatr Soc 2018; 66 (12): 2428–9. DOI: 10.1111/jgs.15637 
69. Almario CV, Chey WD, Spiegel BMR. Increased Risk of COVID-19 Among Users of Proton Pump Inhibitors. Am J Gastroenterol 2020; 115 (10): 1707–15. DOI: 10.14309/ajg.0000000000000798 
70. Karkos PD, Wilson JA. The diagnosis and management of globus pharyngeus: our perspective from the United Kingdom. Curr Opin Otolaryngol Head Neck Surg 2008; 16 (6): 521–4. DOI: 10.1097/MOO.0b013e328316933b
71. McGlashan JA, Johnstone LM, Sykes J et al. The value of a liquid alginate suspension (Gaviscon Advance) in the management of laryngopharyngeal reflux. Eur Arch Otorhinolaryngol 2009; 266 (2): 243–51. DOI: 10.1007/s00405-008-0708-7 
72. Wilkie MD, Fraser HM, Raja H. Gaviscon Advance alone versus co-prescription of Gaviscon Advance and proton pump inhibitors in the treatment of laryngopharyngeal reflux. Eur Arch Otorhinolaryngol 2018; 275 (10): 2515–21. DOI: 10.1007/s00405-018-5079-0
73. Sun J, Yang C, Zhao H et al. Randomised clinical trial: the clinical efficacy and safety of an alginate-antacid (Gaviscon Double Action) versus placebo, for decreasing upper gastrointestinal symptoms in symptomatic gastroesophageal reflux disease (GERD) in China. Aliment Pharmacol Ther 2015; 42 (7): 845–54. DOI: 10.1111/apt.13334
74. Gelardi M, Ciprandi G. Focus on gastroesophageal reflux (GER) and laryngopharyngeal reflux (LPR): new pragmatic insights in clinical practice. J Biol Regul Homeost Agents 2018; 32 (1 Suppl. 2): 41–7.
75. Lechien JR, Bobin F, Muls V et al. Gastroesophageal reflux in laryngopharyngeal reflux patients: Clinical features and therapeutic response. Laryngoscope 2020; 130 (8): E479–89. DOI: 10.1002/lary.28482
76. Lieder A, Issing W. Treatment for resilient cough owing to laryngopharyngeal reflux with a combination of proton pump inhibitor and Gaviscon Advance: how we do it. Clin Otolaryngol 2011; 36 (6): 583–7. DOI: 10.1111/j.1749-4486.2011.02394.x
77. Coyle C, Crawford G, Wilkinson J et al. Randomised clinical trial: addition of alginate-antacid (Gaviscon Double Action) to proton pump inhibitor therapy in patients with breakthrough symptoms. Aliment Pharmacol Ther 2017; 45 (12): 1524–33. DOI: 10.1111/apt.14064
78. Hampson FC, Farndale A, Strugala V et al. Alginate rafts and their characterisation. Int J Pharm 2005; 294: 137–47. DOI: 10.1016/j.ijpharm.2005.01.036
79. Tran T, Lowry A, El-Serag H. Meta-analysis: the efficacy of over-the-counter gastro-oesophageal reflux disease drugs. Aliment Pharmacol Ther 2007; 25 (2): 143–53. DOI: 10.1111/j.1365-2036.2006.03135.x
80. Hampson FC, Jolliffe IG, Bakhtyari A et al. Alginate-antacid combinations: raft formation and gastric retention studies. Drug Dev Ind Pharm 2010; 36: 614–23. DOI: 10.3109/03639040903388290
81. Uspenskii Iu.P., Baryshnikova N.V., Belousova L.N. Use of alginates for different types of heartburn. Consilium Medicum. 2014; 2: 43–6. http://elibrary.ru/item.asp?id=22824128 (in Russian).
82. Kwiatek MA, Roman S, Fareeduddin A et al. An alginate-antacid formulation (Gaviscon Double Action Liquid) can eliminate or displace the postprandial ‘acid pocket’ in symptomatic GERD patients. Aliment Pharmacol Ther 2011; 34: 59–66. DOI: 10.1111/j.1365-2036.2011.04678.x
83. Dettmar PW, Hampson FC, Taubel J et al. The suppression of gastro-oesophageal reflux by alginates. Int J Clin Pract. 2007; 61 (10): 1654–62. DOI: 10.1111/j.1742- 1241.2007.01524.x
84. Dettmar PW, Hampson FC, Taubel J. The suppression of gastro-oesophageal reflux by alginates. The suppression of gastro-oesophageal reflux by alginates. Int J Clin Pract 2007; 61 (10): 1654–62 (in Russian).
85. Thomas E, Wade A, Crawford G et al. Randomised clinical trial: relief of upper gastrointestinal symptoms by an acid pocket-targeting alginate-antacid (Gaviscon Double Action) – a double-blind, placebo-controlled, pilot study in gastrooesophageal reflux disease. Aliment Pharmacol Ther 2014; 39: 595–602. DOI: 10.1111/apt.12640
86. Uzan M, Uzan S, Sureau C, Richard-Berthe C. Heartburn and regurgitation in pregnancy. Efficacy and innocuousness of treatment with Gaviscon suspension. Revue Francaise de Gynecologie et d’Obstetrique 1988; 83 (7–9): 569–72. https://pubmed.ncbi.nlm.nih.gov/2848305/
87. Hutt HJ, Tauber O, Flach D. Gaviscon in the treatment of reflux disease. Results of an observational study. Fortschritte der Medizin 1990; 108: 598–600. https://pubmed.ncbi.nlm.nih.gov/2258131/
88. Lindow SW, Regnéll P, Sykes J, Little S. An open-label, multicentre study to assess the safety and efficacy of a novel reflux suppressant (Gaviscon Advance) in the treatment of heartburn during pregnancy. Int J Clin Pract 2003; 57 (3): 175–9. https://pubmed.ncbi.nlm.nih.gov/12723718/
89. Strugala V, Bassin J, Swales VS et al. Assessment of the Safety and Efficacy of a Raft-Forming Alginate Reflux Suppressant (Liquid Gaviscon) for the Treatment of Heartburn during Pregnancy. ISRN Obstet Gynecol 2012; 2012: 481870. DOI: 10.5402/2012/481870
90. Vasil'ev Iu.V. Geviskon kak proizvodnoe al'ginatov v terapii gastroezofageal'noi refliuksnoi bolezni. RMJ. 2012; 5: 800–2. https://www.elibrary.ru/item.asp?id=17854506 (in Russian).
91. Butov M., Maslennikova E., Kuznetsov P. Geviscon alginate forte in the treatment of gastroesophageal reflux disease. Doctor. 2009; 5: 73–5. https://www.elibrary.ru/item.asp?id=12415698 (in Russian).
92. Onuchina E.V., Brikova S.I., Tsukanov V.V. Ispol'zovanie preparata geviskon dlia kupirovaniia simptomatiki pishchevodnykh, vnepishchevodnykh sindromov i funktsional'noi dispepsii u bol'nykh GERB pozhilogo i starcheskogo vozrasta. Exp Clin Gastroenterol. 2010; 10: 80–6. https://www.elibrary.ru/item.asp?id=15247112 (in Russian).
93. Pakhomova I.G., Uspenskii Iu.P., Pavlova E.Iu. Prospects for the use of Gaviscon forte in the treatment of gastroesophageal reflux disease and NSAID-induced lesions of the esophagus. Consilium Medicum. 2011; 2: 13–7. https://www.elibrary.ru/item.asp?id=21256356 (in Russian).
94. Zvenigorodskaia L.A., Churikova A.A. Osobennosti terapii gastroezofageal'noi refliuksnoi bolezni pri ishemicheskoi bolezni serdtsa. Effect Pharmacother. 2012; 27: 22–7. https://www.elibrary.ru/item.asp?id=21807065 (in Russian).
95. Bulgakov S.A. Gaviscon for the treatment of heartburn attributable to gastroesophageal reflux disease. Farmateka. 2011; 20: 54–8. 
https://www.elibrary.ru/item.asp?id=17271340 (in Russian).
96. Kaliagin A.N., Asner T.V. Gaviscon in the management of patients with extraesophageal manifestations of gastroesophageal reflux disease.  Consilium Medicum. 2013; 1: 14–7. https://www.elibrary.ru/item.asp?id=21256395 (in Russian).
97. Grishechkina I.A., Lisniak M.V., Trukhan D.I. et al. Simptomy gastroezofageal'noi refliuksnoi bolezni i beremennnost. Int J Exp Edu. 2015; 7: 152–53. 
https://elibrary.ru/item.asp?id=23488979 (in Russian).
98. Anikin G.S. The role of alginates in the treatment of gastroesophageal reflux disease. Gastroenterology. Consilium Medicum. 2015; 1: 36–8. https://www.elibrary.ru/item.asp?id=23454653 (in Russian).
99. Trukhan D.I., Grishechkina I.A. Heartburn pregnant therapy: focus on alginate. Consilium Medicum. 2016; 6: 29–34. https://www.elibrary.ru/item.asp?id=27348305 (in Russian).
100. Pakhomova I.G., Zinovieva E.N. Gastroesophageal reflux disease in a polymorbid patient: features of therapy. RMZh. 2017; 10: 760–4. https://www.elibrary.ru/item.asp?id=30282554 (in Russian).
101. Rohof WO, Bennink RJ, Smout AJ et al. An alginate-antacid formulation localizes to the acid pocket to reduce acid reflux in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2013; 11 (12): 1585–91. DOI: 10.1016/j.cgh.2013.04.046

Д.И. Трухан*1, Н.А. Чусова2, О.В. Дрокина1

1 ФГБОУ ВО «Омский государственный медицинский университет» Минздрава России, Омск, Россия;
2 ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России, Москва, Россия 
*dmitry_trukhan@mail.ru

________________________________________________

Dmitry I. Trukhan*1, Natalia A. Chusova2, Olga V. Drokina1

1 Omsk State Medical University, Omsk, Russia;
2 Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia
*dmitry_trukhan@mail.ru